HHS advances development of new monoclonal antibody drug for Ebola

HHS advances development of new monoclonal antibody drug for Ebola

09/21/2015

A novel Ebola virus disease treatment based on three monoclonal antibodies will advance in development through an agreement between the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals, Inc. of Tarrytown, New York.

Read more about today's announcement.